$AXGN
Axogen, Inc.

2024 Q4 Form 10-Q Financial Statement

#000080592824000137 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $48.64M
YoY Change 17.86%
Cost Of Revenue $12.21M
YoY Change 51.76%
Gross Profit $36.44M
YoY Change 9.66%
Gross Profit Margin 74.91%
Selling, General & Admin $29.76M
YoY Change -1.67%
% of Gross Profit 81.67%
Research & Development $6.996M
YoY Change 0.1%
% of Gross Profit 19.2%
Depreciation & Amortization $1.654M
YoY Change 43.33%
% of Gross Profit 4.54%
Operating Expenses $36.75M
YoY Change -1.34%
Operating Profit -$316.0K
YoY Change -92.15%
Interest Expense -$1.584M
YoY Change -291.54%
% of Operating Profit
Other Income/Expense, Net -$1.542M
YoY Change 2309.38%
Pretax Income -$1.858M
YoY Change -54.57%
Income Tax
% Of Pretax Income
Net Earnings -$1.858M
YoY Change -54.56%
Net Earnings / Revenue -3.82%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 44.01M shares 43.83M shares
Diluted Shares Outstanding 43.88M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.53M
YoY Change -24.75%
Cash & Equivalents $18.66M
Short-Term Investments $5.868M
Other Short-Term Assets $7.730M
YoY Change -10.12%
Inventory $29.36M
Prepaid Expenses
Receivables $24.63M
Other Receivables $0.00
Total Short-Term Assets $86.25M
YoY Change -1.36%
LONG-TERM ASSETS
Property, Plant & Equipment $100.5M
YoY Change -2.31%
Goodwill
YoY Change
Intangibles $5.215M
YoY Change 21.62%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $105.7M
YoY Change -1.36%
TOTAL ASSETS
Total Short-Term Assets $86.25M
Total Long-Term Assets $105.7M
Total Assets $192.0M
YoY Change -1.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.18M
YoY Change -17.28%
Accrued Expenses $1.850M
YoY Change 68.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $6.000K
YoY Change
Total Short-Term Liabilities $23.03M
YoY Change -13.56%
LONG-TERM LIABILITIES
Long-Term Debt $47.27M
YoY Change 1.93%
Other Long-Term Liabilities $94.00K
YoY Change -99.61%
Total Long-Term Liabilities $47.37M
YoY Change 2.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.03M
Total Long-Term Liabilities $47.37M
Total Liabilities $92.58M
YoY Change -4.38%
SHAREHOLDERS EQUITY
Retained Earnings -$291.7M
YoY Change 5.16%
Common Stock $391.1M
YoY Change 4.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.41M
YoY Change
Total Liabilities & Shareholders Equity $192.0M
YoY Change -1.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.858M
YoY Change -54.56%
Depreciation, Depletion And Amortization $1.654M
YoY Change 43.33%
Cash From Operating Activities $3.901M
YoY Change 140.8%
INVESTING ACTIVITIES
Capital Expenditures $1.138M
YoY Change -70.82%
Acquisitions
YoY Change
Other Investing Activities -$3.862M
YoY Change -139.01%
Cash From Investing Activities -$5.000M
YoY Change -183.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 572.0K
YoY Change 5620.0%
NET CHANGE
Cash From Operating Activities 3.901M
Cash From Investing Activities -5.000M
Cash From Financing Activities 572.0K
Net Change In Cash -527.0K
YoY Change -106.92%
FREE CASH FLOW
Cash From Operating Activities $3.901M
Capital Expenditures $1.138M
Free Cash Flow $2.763M
YoY Change -221.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000805928
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Axogen, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MN
dei Entity Address Address Line1
EntityAddressAddressLine1
13631 Progress Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Alachua,
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1301878
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32615
dei City Area Code
CityAreaCode
386
dei Local Phone Number
LocalPhoneNumber
462-6800
dei Trading Symbol
TradingSymbol
AXGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44008259 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18662000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31024000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
6000000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
6002000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
5868000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
337000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24629000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25147000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
29363000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
23020000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1730000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2811000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
88004000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
88730000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4531000 usd
CY2024Q3 us-gaap Assets
Assets
191985000 usd
CY2023Q4 us-gaap Assets
Assets
196827000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18924000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6996000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6694000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10834000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9870000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
35729000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-316000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4025000 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
296000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
367000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43882110 shares
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
138000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
103908000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
18276000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
85632000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
1654000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
1154000 usd
us-gaap Depreciation
Depreciation
4831000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
202000 usd
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 us-gaap Assets Current
AssetsCurrent
86252000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
85632000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5215000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21177000 usd
CY2024Q3 axgn Lease Liability Current
LeaseLiabilityCurrent
1856000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23033000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
47272000 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2445000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44002323 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44002323 shares
CY2024Q3 us-gaap Revenues
Revenues
48644000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12206000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9567000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
31704000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19165000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
axgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1543000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
97810000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21063000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20164000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30206000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30481000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
36754000 usd
us-gaap Costs And Expenses
CostsAndExpenses
109706000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
6000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24662000 usd
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
888000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14886000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15562000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28883000 usd
CY2023Q4 axgn Lease Liability Current
LeaseLiabilityCurrent
1547000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30430000 usd
CY2023Q4 axgn Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
21142000 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2987000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilitiesNoncurrent
CY2024Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilityCurrent
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilitiesNoncurrent
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
46603000 usd
CY2024Q3 axgn Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
19734000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
94000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
92578000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
101162000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
431000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
390677000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
376530000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291710000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281296000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
99407000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
95665000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
191985000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196827000 usd
CY2023Q3 us-gaap Revenues
Revenues
41271000 usd
us-gaap Revenues
Revenues
137933000 usd
us-gaap Revenues
Revenues
116090000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33531000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26242000 usd
us-gaap Gross Profit
GrossProfit
104402000 usd
us-gaap Gross Profit
GrossProfit
89848000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
58437000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
57471000 usd
us-gaap Costs And Expenses
CostsAndExpenses
108116000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5304000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18268000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
816000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
1151000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43882110 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43022328 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Lease Cost
LeaseCost
3673000 usd
us-gaap Lease Cost
LeaseCost
3871000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1541000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21123000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
19000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
14000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1096
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0681
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
47272000 usd
CY2024Q3 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
CY2023Q3 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1043000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
225000 usd
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
224000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
669000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
6000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilityCurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilityCurrent
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilitiesNoncurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilityCurrent
CY2024Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.axogeninc.com/20240930#LeaseLiabilitiesNoncurrent
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43124496 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43124496 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
440000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
36438000 usd
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
90000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
0 usd
us-gaap Sublease Income
SubleaseIncome
90000 usd
us-gaap Sublease Income
SubleaseIncome
0 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1893000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
827000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
6405000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
992000 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
13000 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
402000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
542000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
649000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-153000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-363000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1542000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-64000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5110000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
445000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1858000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4089000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10414000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17823000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17823000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43022328 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43610481 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43610481 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42821284 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42821284 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Net Income Loss
NetIncomeLoss
-10414000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17823000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4831000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2660000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
889000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
826000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
202000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
214000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
669000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
666000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
604000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-311000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
542000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
649000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
95000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
660000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12830000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13091000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
85000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
766000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6343000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4114000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1189000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
623000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7125000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3012000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1303000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1012000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
495000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-14000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4200000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5505000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2431000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12409000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5773000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10203000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
42874000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1280000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
732000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9484000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19530000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
7000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1326000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1543000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1320000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1536000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12364000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15561000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37026000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21535000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24662000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37096000 usd
us-gaap Interest Paid Net
InterestPaidNet
5736000 usd
us-gaap Interest Paid Net
InterestPaidNet
325000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
114000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
853000 usd
axgn Noncash Right Of Use Assets And Operating Lease Liability
NoncashRightOfUseAssetsAndOperatingLeaseLiability
0 usd
axgn Noncash Right Of Use Assets And Operating Lease Liability
NoncashRightOfUseAssetsAndOperatingLeaseLiability
366000 usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
14000 usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
420000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
95687000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1858000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5004000 usd
CY2024Q3 axgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
574000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
99407000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
95665000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10414000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12830000 usd
axgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1326000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
99407000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
97152000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4089000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4747000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
97810000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
100999000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17823000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13091000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Nature of Business</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen, Inc. (together with its wholly-owned subsidiaries, the “Company”) was incorporated in Minnesota. Our business is focused on the science, development and commercialization of the technologies used for peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avive+ Soft Tissue Matrix™, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.</span></div>The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Reclassifications</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective in the first quarter of 2024, the Company voluntarily changed its accounting policy for shipping and handling costs. Under the new accounting policy, these costs are included in Costs of goods sold, whereas they were previously included in Sales and marketing expenses. Including these expenses in Costs of goods sold better aligns these costs with the related revenue in the gross profit calculation. Although the prior method of accounting continues to be an accepted alternative, the new accounting policy is more widely used in the industry and provides improved comparability of the Company's financial statements to its peers. This change in accounting policy has been applied retrospectively. The consolidated statement of operations for the three and nine months ended September 30, 2023, has been reclassified to reflect this change in accounting policy. The impact of this reclassification was an increase of $1,460 and $4,204 to Cost of goods sold for the three and nine months ended September 30, 2023, respectively, and a corresponding decrease to Sales and marketing expenses in the same periods. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective in the first quarter of 2024, the Company also ceased allocating certain costs to and from certain departments. Previously such costs had been allocated based on the Company’s estimate of the proportionate share of total expense to Cost of goods sold, Sales and marketing, Research and development, and General and administrative. The Company determined that these changes would better reflect industry practice and would provide more meaningful information as well as increased transparency of its operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> To conform the 2023 presentation to the current quarter and year to date presentation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$1,035</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3,019 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was reclassified to General and administrative, of which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$295</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$867 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was previously included in Research and development, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$803</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$2,209 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was previously included in Sales and marketing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$63 and $58</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was previously included in Cost of goods sold for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2023, respectively, in the condensed consolidated statement of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These reclassifications had no impact on net revenue, loss from operations, net loss, or loss per common share for prior periods and do not represent a restatement of the Company's previously issued condensed consolidated financial statements.</span></div>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18162000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18662000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31024000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
6002000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37026000 usd
CY2024Q3 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
378000 usd
CY2023Q3 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
0 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
544000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
155000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
23766000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13545000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
900000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2120000 usd
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4697000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7355000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
29363000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
23020000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1518000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1342000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
138000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
102427000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
13697000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
88730000 usd
us-gaap Depreciation
Depreciation
2660000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5691000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1009000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4682000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6006000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1907000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4099000 usd
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6224000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1009000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5215000 usd
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6438000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1907000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4531000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
70000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
214000 usd
CY2023Q4 axgn Number Of Settlement Scenarios Concluded
NumberOfSettlementScenariosConcluded
1 product
CY2024Q3 us-gaap Lease Cost
LeaseCost
1183000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
1327000 usd
CY2024Q3 axgn Operating Lease Right Of Use Asset Excluding Sublease Receivable
OperatingLeaseRightOfUseAssetExcludingSubleaseReceivable
14614000 usd
CY2023Q4 axgn Operating Lease Right Of Use Asset Excluding Sublease Receivable
OperatingLeaseRightOfUseAssetExcludingSubleaseReceivable
15562000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1850000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19720000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
272000 usd
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
0 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
28000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19000 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M6D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1099
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1322
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid Remainder Of Fiscal Year
LesseeOperatingAndFinancingLeaseLiabilityToBePaidRemainderOfFiscalYear
999000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid Year One
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne
4143000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Two
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo
4278000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Three
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree
3115000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid Year Four
LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour
3113000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid After Year Four
LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFour
18567000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability To Be Paid
LesseeOperatingAndFinancingLeaseLiabilityToBePaid
34215000 usd
CY2024Q3 axgn Lessee Operating And Financing Lease Liability Undiscounted Excess Amount
LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount
12625000 usd
CY2024Q3 axgn Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
21590000 usd
CY2024Q3 axgn Operating And Financing Lease Liability Current
OperatingAndFinancingLeaseLiabilityCurrent
1856000 usd
CY2024Q3 axgn Operating And Financing Lease Liability Noncurrent
OperatingAndFinancingLeaseLiabilityNoncurrent
19734000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2728000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3397000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
46603000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
5240000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
666000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
6002000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5004000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4747000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12830000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13091000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1858000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4089000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43882110 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43022328 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43610481 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42821284 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43882110 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43022328 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43610481 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42821284 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000805928-24-000137-index-headers.html Edgar Link pending
0000805928-24-000137-index.html Edgar Link pending
0000805928-24-000137.txt Edgar Link pending
0000805928-24-000137-xbrl.zip Edgar Link pending
axgn-20240930.htm Edgar Link pending
axgn-20240930.xsd Edgar Link pending
axgnfy24q3ex311.htm Edgar Link pending
axgnfy24q3ex312.htm Edgar Link pending
axgnfy24q3ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
axgn-20240930_def.xml Edgar Link unprocessable
axgn-20240930_lab.xml Edgar Link unprocessable
axgn-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
axgn-20240930_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
axgn-20240930_cal.xml Edgar Link unprocessable